Rapid benefit of intravenous pulse loading of clomipramine in obsessive- compulsive disorder
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The authors conducted a randomized, double-blind, placebo-controlled trial of intravenous versus oral pulse loading of clomipramine in patients with obsessive-compulsive disorder to test two hypotheses: 1) intravenous pulse loading will cause greater immediate improvement than oral pulse loading and 2) patients who respond to pulse loading will continue to improve during 8 weeks of oral clomipramine treatment. METHOD: Fifteen patients with DSM-III-R obsessive-compulsive disorder of at least 1 year's duration and baseline Yale-Brown Obsessive Compulsive Scale scores of 17 or higher were enrolled in the study. Yale-Brown scale ratings were made 4.5 days after double-blind oral or intravenous pulse loading of clomipramine, and patients were then given 150 mg/day of oral clomipramine with increases of 25 mg every 4 days to 250 mg/day as tolerated or, in two cases, other selective serotonin reuptake inhibitors (SSRIs). RESULTS: The first hypothesis was confirmed: 4.5 days after the second pulse-loaded dose, six of seven patients given intravenous clomipramine but only one of eight given oral medication responded to the drug. After 8 weeks of oral clomipramine, the results partially supported the second hypothesis: four of six patients who had responded to intravenous clomipramine continued their improvement, but those who had responded to pulse loading did not improve statistically significantly more than those who had not. CONCLUSIONS: Intravenous pulse loading of clomipramine may be a valuable new treatment for obsessive-compulsive disorder, particularly for patients who have failed oral treatment trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antidepressant drug action in a transgenic mouse model of the endocrine changes seen in depression
Pepin, M. C., Pothier, F., & Barden, N. (1992) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09284-3 · Cited by 105 · cited 1×
“For example, desipramine increases hypothalamic glucocorticoid receptor mRNA (29), and imipramine decreases tyrosine hydroxylase mRNA in the locus ceruleus (30).”
Background
Research works printed but not linked: 31
- 10.1001/archpsyc.1989.01810110048007 · DOI · Paper page
- 10.1001/archpsyc.1991.01810320054008 · DOI · Paper page
- 10.1097/00004714-199604000-00004 · DOI · Paper page
- Goodman WK, 1992, J Clin Psychiatry, 53, 29
- 10.1001/archpsyc.1995.03950130053006 · DOI · Paper page
- Wheadon DE, 1993, American College of Neuropsychopharmacology 32nd Annual Meeting. Nashville, Tenn, ACN, 193
- Jenike MA, 1994, J Clin Psychiatry, 55, 11
- 10.1016/S0033-3182(71)71497-2 · DOI
- 10.1177/030006057300100523 · DOI
- Rack PH, 1977, J Int Med Res, 5, 81, 10.1177/030006057700502S16 · doi:10.1177/030006057700502s16
- 10.1177/030006057300100506 · doi:10.1177/030006057300100506
- Faravelli C, 1987, Psychopharmacol Bull, 23, 459
- 10.1177/030006057300100525 · doi:10.1177/030006057300100525
- 10.1177/070674378402900211 · DOI
- Warneke LB, 1985, J Clin Psychiatry, 46, 100
- 10.1177/070674378903400902 · DOI
- 10.1176/jnp.4.1.70 · DOI · Paper page
- Koran LM, 1994, J Clin Psychopharmacol, 14, 216
- Sallee FR, 1989, Psychopharmacol Bull, 25, 114
- Spitzer RL, 1990, Gibbon M
- 10.1001/archpsyc.1989.01810010031005 · DOI · Paper page
- 10.1210/jcem-68-3-632 · DOI · Paper page
- Carson S, 1991, American College of Neuropsychopharmacology 30th Annual Meeting. Nashville, Tenn, ACN, 226
- 10.1111/j.2044-8260.1967.tb00530.x · DOI · Paper page
- Mavissakalian MR, 1990, J Clin Psychopharmacology (Berl), 10, 261
- 10.1016/0022-3956(95)00042-9 · DOI
- 10.1111/j.2042-7158.1977.tb11255.x · doi:10.1111/j.2042-7158.1977.tb11255.x
- 10.1001/archpsyc.1991.01810300052007 · DOI
- 10.1172/JCI115086 · DOI · Paper page
- 10.1016/0028-3908(94)90073-6 · DOI
- Potter WZ, 1980, Psychopharmacol Bull, 16, 32
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Treatment non-response in OCD: methodological issues and operational definitions
Pallanti, S., Hollander, E., Bienstock, C., Koran, L., Leckman, J., Marazziti, D., Pato, M., Stein, D., Zohar, J., & International Treatment Refractory OCD Consortium (2002) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145702002900 · Cited by 416
Self-citationPallanti, S., & Quercioli, L. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.11.028 · Cited by 408
“In a double-blind, pulse-loaded study involving IV clomipramine, Koran et al. (1997) noted that the subjects on IV clomipramine (n =7) demonstrated a more rapid response (decrease in Y-BOCS score by >25% by day 4.5) than those on oral clomipramine (n =8).”
BackgroundInfluentialSelf-citationSaxena, S. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00082-2 · Cited by 379
“These criteria were chosen based on earlier use of these cutoffs for response in clinical studies (e.g., Montgomery et al. 1993; Wood et al. 1993; Koran et al. 1997).”
MethodStein, D. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09620-4 · Cited by 352
Evidence-based pharmacotherapy of obsessive-compulsive disorder
Fineberg, N. A., Brown, A., Reghunandanan, S., & Pampaloni, I. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001829 · Cited by 336
“In another study, pulse loading with intravenous clomipramine produced a large and rapid decrease in obsessive symptoms, but oral pulse loading did not, and the early advantages were not sustained over treatment (Koran et al., 1997).”
BackgroundPharmacotherapy of Obsessive-compulsive Disorder and Obsessive-Compulsive Spectrum Disorders
Denys, D. (2006) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2006.02.013 · Cited by 213
Goodman, W. K., Grice, D. E., Lapidus, K. A. B., & Coffey, B. J. (2014) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2014.06.004 · Cited by 221
King, R. A., Leonard, H., & March, J. (1998) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199810001-00003 · Cited by 200
Fineberg, N. A., Reghunandanan, S., Simpson, H. B., Phillips, K. A., Richter, M. A., Matthews, K., Stein, D. J., Sareen, J., Brown, A., & Sookman, D. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2014.12.003 · Cited by 150
Unmet need for services and interventions among adolescents with mental disorders
Wang, P. S., Sherrill, J., & Vitiello, B. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.1.1 · Cited by 123
Pharmacotherapy of obsessive–compulsive disorder: evidence-based treatment and beyond
Fineberg, N. A., Reghunandanan, S., Brown, A., & Pampaloni, I. (2013) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867412461958 · Cited by 122
“Similarly, Koran et al. (1997) demonstrated that pulseloading with intravenous clomipramine produced a large and rapid decrease in obsessive symptoms (but oral pulse loading did not), though the early advantages disappeared later.”
BackgroundBokor, G., & Anderson, P. D. (2014) · Journal of Pharmacy Practice · doi:10.1177/0897190014521996 · Cited by 79
Minelli, A., Bortolomasi, M., Scassellati, C., Salvoro, B., Avesani, M., & Manganotti, P. (2010) · Brain Stimulation · doi:10.1016/j.brs.2009.04.003 · Cited by 31
Ruiz (2000) · doi:10.1097/00131746-200005000-00002 · Cited by 14
“conducted a double-blind trial of pulse IV versus pulse oral CMI in 15 patients with oCD.(92) Pharmacological nonresponse was not an entry criterion for the study.”
BackgroundMethod
Metadata
- Venue
- American Journal of Psychiatry
- Published
- 1997-03-01
- Volume
- 154
- Issue
- 3
- Pages
- 396-401
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W1534208980
- Cited by
- 102
- References
- 1
- FWCI
- 9.63
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.